Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis

被引:8
|
作者
Ohashi, Kadoaki [1 ]
Ninomiya, Kiichiro [1 ]
Yoshioka, Hiroshige [2 ,20 ]
Bessho, Akihiro [3 ]
Shibayama, Takuo [4 ]
Aoe, Keisuke [5 ]
Ishikawa, Nobuhisa [6 ]
Kozuki, Toshiyuki [7 ]
Kawai, Haruyuki [8 ]
Kuyama, Shoichi [9 ]
Miyoshi, Seigo [10 ]
Fujitaka, Kazunori [11 ]
Obata, Hideto [12 ]
Tsubata, Yukari [13 ]
Awaya, Yoshikazu [14 ]
Inoue, Masaaki [15 ]
Inoue, Koji [16 ]
Horita, Naokatsu [17 ]
Yanai, Hiroyuki [18 ]
Hotta, Katsuyuki [19 ]
Kiura, Katsuyuki [1 ]
机构
[1] Okayama Univ Hosp, Dept Resp Med, Okayama, Japan
[2] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan
[3] Japanese Red Cross Okayama Hosp, Dept Resp Med, Okayama, Japan
[4] Natl Hosp Org, Dept Resp Med, Okayama Med Ctr, Okayama, Japan
[5] Natl Hosp Org, Dept Med Oncol, Yamaguchi Ube Med Ctr, Ube, Yamaguchi, Japan
[6] Hiroshima Prefectural Hosp, Dept Resp Med, Hiroshima, Japan
[7] Natl Hosp Org, Shikoku Canc Ctr, Dept Thorac Oncol & Med, Shikoku, Ehime, Japan
[8] Okayama Saiseikai Gen Hosp, Dept Internal Med, Okayama, Japan
[9] Iwakuni Med Ctr, Dept Resp Med, Iwakuni, Japan
[10] Ehime Univ, Grad Sch Med, Dept Cardiol Pulmonol Hypertens & Nephrol, Matsuyama, Ehime, Japan
[11] Hiroshima Univ Hosp, Dept Resp Med, Hiroshima, Japan
[12] Yamaguchi Ken Saiseikai Shimonoseki Gen Hosp, Dept Resp Med, Shimonoseki, Yamaguchi, Japan
[13] Shimane Univ, Fac Med, Div Med Oncol & Resp Med, Dept Internal Med, Matsue, Shimane, Japan
[14] Miyoshi Cent Hosp, Dept Resp Med, Saitama, Japan
[15] Shimonoseki City Hosp, Dept Chest Surg, Shimonoseki, Yamaguchi, Japan
[16] Ehime Prefectural Cent Hosp, Dept Resp Med, Matsuyama, Ehime, Japan
[17] Kure Kyosai Hosp, Dept Resp Med, Kure, Hiroshima, Japan
[18] Okayama Univ Hosp, Dept Pathol, Okayama, Japan
[19] Okayama Univ Hosp, Ctr Innovat Clin Med, 2-5-1 Shikata Cho Kita Ward, Okayama 7008558, Japan
[20] Kansai Med Univ Hosp, Dept Thorac Oncol, Hirakata, Osaka, Japan
关键词
Epidermal growth factor receptor mutations; Performance status; Human epidermal growth factor receptor-2; Time-To-Treatment failure; GROWTH-FACTOR RECEPTOR; ACQUIRED-RESISTANCE; TRASTUZUMAB EMTANSINE; GENE-MUTATIONS; PHASE-II; CANCER; MUTANT; AMPLIFICATION; OVEREXPRESSION; ADENOCARCINOMA;
D O I
10.1016/j.lungcan.2020.09.024
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are standard treatment for EGFR-mutated non-small-cell lung carcinoma (NSCLC); however, a biomarker to predict their efficacy has not been established. Although human epidermal growth factor receptor-2 (HER2) aberrations constitute a potential mechanism for acquired resistance to EGFR-TKIs, the impact of HER2 on EGFR-TKI treatment outcomes has not been systematically evaluated. In this post-hoc subgroup study, we examined the impact of HER2 on the effect of EGFR-TKIs in patients with NSCLC harboring EGFR mutations. Materials and Methods: Of 1126 patients with NSCLC enrolled into a prospective cohort study (HER2-CS study), we analyzed data of 356 (32 %) patients with EGFR-mutant tumors. HER2 protein expression levels were determined by immunohistochemistry (IHC) with the gastric cancer criteria. Patients were divided either to an HER2-P group (HER2-IHC2+/3+) or an HER2-N group (HER2-IHC0/1+). We primarily assessed differences in the time-to-treatment failure (TTF) of EGFR-TKI between the groups. Results: The HER2 scoring was as follows: IHC0 (n = 76, 21 %), IHC1+ (n = 199, 56 %), IHC2+ (n = 72, 20 %), and IHC3+ (n = 9, 3 %). The patients' demographics were similar in the HER2-P and HER2-N groups. The HER2-P group showed a significantly shorter EGFR-TKI TTF than the HER2-N group (hazard ratio [HR]: 1.657, 95 % confidence interval [CI]: 1.076-2.552; median: 13.3 vs. 19.1 months). The magnitude of the negative impact of TTF was especially dependent on performance status (PS). HER2 expression significantly deteriorated the TTF in the subgroup with PS 2 (HR: 5.497, 95 % CI: 1.510-20.02), but not in that with better PS (HR: 1.437, 95 % CI: 0.899-2.298) (pinteraction = 0.015). Conclusion: In the current cohort, HER2 protein expression in EGFR-mutant NSCLC may have a negative impact on the effect of EGFR-TKIs, the effect of which was PS dependent.
引用
收藏
页码:83 / 89
页数:7
相关论文
共 50 条
  • [41] HER2 gene-amplified human breast cancer cells harboring a gatekeeper T768M mutation in HER2 overexpress EGFR ligands and are sensitive to dual therapeutic blockade of EGFR and HER2
    Ghosh, Ritwik
    Narasanna, Archana
    Chakrabarty, Anindita
    Engelman, Jeffrey A.
    Arteaga, Carlos L.
    CANCER RESEARCH, 2012, 72
  • [42] HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer
    Takezawa, Ken
    Melnick, Mary Ann
    Riely, Greg
    Kris, Mark
    Miller, Vincent
    Ladanyi, Marc
    Politi, Katerina
    Pao, William
    Pirazzoli, Valentina
    Song, Xiaoling
    Arcila, Maria
    De Stanchina, Elisa
    Ohashi, Kadoaki
    Janjigian, Yelena
    Spitzler, Paula
    Nebhan, Caroline
    CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [43] Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2
    Rexer, Brent N.
    Ghosh, Ritwik
    Narasanna, Archana
    Estrada, Monica Valeria
    Chakrabarty, Anindita
    Song, Youngchul
    Engelman, Jeffrey A.
    Arteaga, Carlos L.
    CLINICAL CANCER RESEARCH, 2013, 19 (19) : 5390 - 5401
  • [44] A global phase 1b study of ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, in patients with advanced solid tumors harboring EGFR Exon 20 or HER2 alterations
    Hong, M. H.
    Spira, A. I.
    Lee, K. H.
    Cho, E. K.
    Han, J-Y.
    Shim, B. Y.
    Lee, J-S.
    Kao, S. C-H.
    Kim, S-W.
    Khattak, A.
    Patel, M.
    Xu, R.
    Wang, J.
    Ariazi, E.
    Daemen, A.
    Maneval, E. Chow
    Multani, P. S.
    Patel, R.
    Ahn, M-J.
    ANNALS OF ONCOLOGY, 2023, 34
  • [45] Performance of AmoyDx HER2 mutation detection kit and AmoyDx Pan Lung Cancer PCR Panel for detection of common HER2 and/or EGFR mutations
    Sheng, M.
    Brown, H.
    Dearden, S.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S334 - S334
  • [46] Effects of HER2 and HER3 on EGFR trafficking and localization - a modelling study
    Resat, H
    Shankaran, H
    Wiley, H
    MOLECULAR BIOLOGY OF THE CELL, 2004, 15 : 13A - 13A
  • [47] TH-4000, a hypoxia-activated EGFR/Her2 inhibitor to treat EGFR-TKI resistant T790M-negative NSCLC
    Patterson, Adam Vorn
    Silva, Shevan
    Guise, Chris
    Bull, Matthew
    Abbattista, Maria
    Hsu, Annie
    Sun, Jessica D.
    Hart, Charles P.
    Pearce, Tillman E.
    Smaill, Jeff Bruce
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [48] HER2/neu expression in malignant lung tumors
    Hirsch, FR
    Franklin, WA
    Veve, R
    Varella-Garcia, M
    Bunn, PA
    SEMINARS IN ONCOLOGY, 2002, 29 (01) : 51 - 58
  • [49] EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases
    Wei, Qichun
    Chen, Lirong
    Sheng, Liming
    Nordgren, Hans
    Wester, Kenneth
    Carlsson, Jorgen
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2007, 31 (03) : 493 - 499
  • [50] EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma
    Livasy, CA
    Reading, FC
    Moore, DT
    Boggess, JF
    Lininger, RA
    GYNECOLOGIC ONCOLOGY, 2006, 100 (01) : 101 - 106